Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

This study has been completed.
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Genentech
Bristol-Myers Squibb
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Harvard Vanguard Medical Associates
Brigham and Women's Hospital
Information provided by (Responsible Party):
Harold J. Burstein, MD, PhD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00136539
First received: August 26, 2005
Last updated: February 15, 2013
Last verified: February 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2012
  Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)